Hospital
Nazareth Hospital
Nazareth Hospital was paid $28.16M by Medicaid between Jan 2019 and Dec 2024, across 177 billing codes. Its largest line is 99284, emergency room visit (serious) — 31% of everything it billed.
33Billing provider infoNAZARETH HOSPITAL
PHILADELPHIA, PA 19152
PHILADELPHIA, PA 19152
33aNPI1124023015assigned 06/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$28.16M
24GClaims318,353
24DCodes billed177
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#7 of 154
Median peer was paid$2.82M
This provider vs. median10.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 537 | $48K | |
| 2020 | 55,061 | $3.24M | |
| 2021 | 96,302 | $8.36M | |
| 2022 | 37,746 | $5.56M | |
| 2023 | 61,404 | $5.70M | |
| 2024incomplete | 67,303 | $5.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 29,375 | 27,848 | $8.82M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 23,205 | 22,491 | $6.44M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 18,212 | 17,131 | $5.79M |
| G0378 | Hospital observation service, per hour | 12% | 2,241 | 1,830 | $3.52M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.5% | 6,789 | 6,620 | $1.83M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 166 | 163 | $274K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | <1% | 3,481 | 907 | $264K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,948 | 3,781 | $121K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,098 | 533 | $117K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 270 | 156 | $92K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 317 | 308 | $80K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 318 | 307 | $54K |
165 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,436 | $53K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 116 | $43K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 342 | $38K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,379 | $38K |
| 93975 | <1% | 733 | $34K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,217 | $33K |
| 80053 | Comprehensive metabolic panel | <1% | 18,361 | $30K |
| 73630 | <1% | 1,198 | $24K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 222 | $22K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,522 | $21K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,709 | $20K |
| 97161 | <1% | 362 | $20K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,779 | $17K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,505 | $16K |
| 93970 | <1% | 166 | $15K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 544 | $15K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 102 | $15K |
| 76641 | <1% | 178 | $14K | |
| 76830 | Ultrasound, transvaginal | <1% | 436 | $13K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 323 | $12K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 156 | $12K |
| 84484 | <1% | 7,049 | $11K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,166 | $11K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 396 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 327 | $10K |
| 72100 | <1% | 296 | $9K | |
| 0012A | <1% | 131 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 386 | $9K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,189 | $9K |
| 93971 | <1% | 238 | $9K | |
| 0011A | <1% | 170 | $8K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 311 | $8K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 362 | $8K |
| 93017 | <1% | 104 | $7K | |
| 73610 | <1% | 482 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,504 | $6K |
| 77066 | Tomosynthesis, mammo | <1% | 42 | $6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,531 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 744 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,403 | $6K |
| 76801 | <1% | 404 | $5K | |
| 93041 | <1% | 7,614 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 189 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 312 | $5K |
| 73564 | <1% | 402 | $4K | |
| 83690 | <1% | 6,072 | $4K | |
| 73030 | <1% | 305 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 279 | $3K |
| 83880 | <1% | 999 | $3K | |
| 73130 | <1% | 468 | $3K | |
| 83735 | <1% | 3,956 | $3K | |
| 85730 | <1% | 2,938 | $3K | |
| 73502 | <1% | 99 | $3K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 12 | $3K |
| 85610 | <1% | 3,239 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 324 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 689 | $2K |
| 76770 | <1% | 37 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $2K |
| 81001 | <1% | 7,023 | $2K | |
| 84703 | <1% | 1,994 | $2K | |
| 72070 | <1% | 43 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 66 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,287 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,868 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 146 | $2K |
| 90715 | <1% | 407 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,381 | $2K |
| 74018 | <1% | 40 | $1K | |
| 72040 | <1% | 28 | $1K | |
| 70486 | <1% | 72 | $1K | |
| 73110 | <1% | 154 | $1K | |
| 84702 | <1% | 656 | $1K | |
| 85027 | <1% | 1,009 | $1K | |
| 71250 | <1% | 42 | $1K | |
| 93350 | <1% | 12 | $1K | |
| 80061 | Lipid panel | <1% | 192 | $1K |
| 80177 | <1% | 78 | $954.50 | |
| 84100 | <1% | 1,757 | $899.54 | |
| C1769 | Guide wire | <1% | 28 | $873.61 |
| 86900 | <1% | 632 | $836.25 | |
| 81003 | <1% | 2,740 | $808.66 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $749.08 |
| 81025 | <1% | 5,385 | $722.81 | |
| 86850 | <1% | 418 | $674.83 | |
| 87186 | <1% | 430 | $602.70 | |
| 80076 | <1% | 358 | $574.19 | |
| 88342 | <1% | 65 | $554.76 | |
| 85007 | <1% | 852 | $543.19 | |
| 87077 | <1% | 480 | $512.50 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 29 | $495.31 |
| 87081 | <1% | 778 | $493.14 | |
| 86901 | <1% | 626 | $485.46 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,514 | $481.45 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 835 | $478.77 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 835 | $478.23 |
| 85379 | <1% | 714 | $471.17 | |
| 83605 | <1% | 619 | $464.79 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 222 | $462.59 |
| 97165 | <1% | 24 | $445.30 | |
| 87040 | <1% | 319 | $444.48 | |
| 82803 | <1% | 153 | $393.88 | |
| 0352U | <1% | 91 | $387.90 | |
| 82550 | <1% | 405 | $384.01 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 198 | $351.86 |
| 87641 | <1% | 13 | $341.55 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 366 | $314.16 |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 32 | $264.81 |
| 76870 | <1% | 13 | $227.43 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 500 | $207.39 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 343 | $202.47 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,222 | $198.94 |
| 93976 | <1% | 48 | $174.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 431 | $173.65 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 153 | $166.41 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 442 | $158.64 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 13 | $154.72 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,804 | $144.37 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 12 | $142.18 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 742 | $141.17 |
| 73590 | <1% | 18 | $131.06 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 984 | $123.12 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,033 | $122.73 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,004 | $121.49 |
| 87210 | <1% | 308 | $113.49 | |
| 80320 | <1% | 17 | $111.13 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 13 | $97.34 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,298 | $91.29 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,250 | $89.21 |
| 82607 | <1% | 12 | $89.18 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,118 | $84.06 |
| 82746 | <1% | 12 | $82.32 | |
| 12001 | <1% | 25 | $71.06 | |
| 87430 | <1% | 219 | $69.30 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 972 | $59.18 |
| 73080 | <1% | 30 | $57.04 | |
| 97116 | <1% | 71 | $51.77 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 53 | $28.34 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,009 | $26.47 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 750 | $24.70 |
| 88304 | <1% | 14 | $18.86 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 27 | $16.62 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 468 | $16.22 |
| 82150 | <1% | 57 | $15.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 143 | $10.37 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 519 | $9.17 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,002 | $9.08 |
| A9270 | Non-covered item or service | <1% | 12,420 | $7.74 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 62 | $7.65 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 679 | $5.88 |
| 87147 | <1% | 12 | $5.26 | |
| 82010 | <1% | 14 | $5.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 14 | $3.67 |
| 86140 | <1% | 15 | $3.55 | |
| J1815 | Injection, insulin, per 5 units | 0% | 485 | $0.00 |
| 96376 | 0% | 97 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 12 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 294 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 44 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 15 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 129 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 36 | $0.00 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 33 | $0.00 |
| 84439 | 0% | 14 | $0.00 | |
| 87420 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWAJDA, DAVID (CHIEF FINANCIAL OFFICER, VP FINANCE)